- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Alvotech: Transactions of Managers and Closely Associated Persons | 11 | GlobeNewswire (USA) | ||
| 06.01. | Alvotech announces CEO transition | 10 | Seeking Alpha | ||
| 06.01. | Alvotech Appoints Lisa Graver As CEO, Rbert Wessman To Continue As Executive Chairman | 3 | RTTNews | ||
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| 06.01. | Alvotech names Lisa Graver as new CEO as founder steps back | 4 | Investing.com | ||
| 06.01. | Alvotech announces planned CEO succession and leadership transition | 317 | GlobeNewswire (Europe) | R- bert Wessman to continue serving as Executive Chairman in full-time capacityLisa Graver appointed Chief Executive Officer REYKJAVIK, ICELAND (January 6, 2026) - Alvotech (NASDAQ: ALVO), a global... ► Artikel lesen | |
| 06.01. | Alvotech Secures $100 Million Term Loan Facility Led By GoldenTree | 12 | pulse2.com | ||
| 02.01. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 31.12.25 | Alvotech Secures Term Loan Facility of USD 100 Million | 6 | GlobeNewswire (USA) | ||
| 29.12.25 | Alvotech: Changes in company's own shares | 13 | GlobeNewswire (USA) | ||
| 23.12.25 | Alvotech - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Alvotech's Financial Calendar for 2026 | 17 | GlobeNewswire (USA) | ||
| 22.12.25 | Alvotech announces European launch of biosimilar to Simponi | 14 | Seeking Alpha | ||
| 22.12.25 | Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma | 371 | GlobeNewswire (Europe) | Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) - Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the... ► Artikel lesen | |
| 19.12.25 | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | 19 | FiercePharma | ||
| 19.12.25 | Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. | 16 | Seeking Alpha | ||
| 19.12.25 | Teva Pharmaceutical Industries Ltd: Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 978 | GlobeNewswire (Europe) | According to the settlement agreement, the proposed biosimilar to Eylea (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances
REYKJAVIK... ► Artikel lesen | |
| 19.12.25 | Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 433 | GlobeNewswire (Europe) | REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of... ► Artikel lesen | |
| 17.12.25 | Hagens Berman Sobol Shapiro LLP: Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman | 247 | PR Newswire | SAN FRANCISCO, Dec. 17, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over... ► Artikel lesen | |
| 17.12.25 | Alvotech - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.12.25 | Alvotech to raise $100M via convertible bonds, provides 2026 forecast | 7 | Seeking Alpha |
1 2 3 4 5 Weiter >>
122 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 1,420 | -0,70 % | Lineage Cell Therapeutics highlights 2025 achievements in cell therapy | ||
| IMMUNOME | 22,850 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 9,560 | 0,00 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | 0,00 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| KYMERA THERAPEUTICS | 71,12 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 297,74 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,640 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| NUVALENT | 106,16 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,500 | 0,00 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| DISC MEDICINE | 71,04 | 0,00 % | Disc Medicine Inc: Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer | WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,240 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,280 | 0,00 % | Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept | ||
| ARCELLX | 68,32 | 0,00 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| TARSUS PHARMACEUTICALS | 73,65 | -2,18 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ALUMIS | 24,170 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen |
ALVOTECH SDR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,880 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.